Spero Therapeutics reports Q1 2023 net loss of $13.3M; provides pipeline updates for SPR720, tebipenem HBr, and SPR206

Spero Therapeutics, Inc.

2023-Q1 EPS reported -$0.25 revenue$2,069,000

Net loss of $13.3M ($0.25 per share) in Q1 2023, compared to net loss of $32.8M ($1.01 per share) in Q1 2022.
Cash and cash equivalents of $96.3M as of March 31, 2023; company expects sufficient funding beyond 2024.
SPR720 Phase 2 trial in NTM-PD on track for top line data readout in first half of 2024.
Tebipenem HBr: SPA agreement update expected mid-2023; Phase 3 cUTI trial initiation expected in 2H 2023.
SPR206: IND submission for Phase 2 trial in hospital-acquired/ventilator-associated bacterial pneumonia expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Spero Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-142023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.